Physician
Internal Medicine
Dr. Kari L. Mattson, MD
|
|
Give Review
Kari Mattson practices Internal Medicine. She over the years received 1 awards: "Meaningful Use Stage 1 Certification". Kari Mattson is a published doctor. She has 85 papers published. The most current publication "Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC." She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines.
- Radiation pneumonitis and fibrosis following split-course radiation therapy for lung cancer. A radiologic and physiologic study.
- A broad amplification pattern at 3q in squamous cell lung cancer--a fluorescence in situ hybridization study.
- Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung.
- Interferon-mediated in vivo induction of beta 2-microglobulin on small-cell lung cancers and mid-gut carcinoids.
- [Interferon treatment in small-cell lung cancer].
- Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
- Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival.
- Natural interferon alfa as maintenance therapy for small cell lung cancer.
- Effect of interferon-gamma on biogenic amine metabolism, electroencephalographic recordings, and transient potentials.
- DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma.
- Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
- A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.
- Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer.
- Subcutaneously administered recombinant interferon-gamma in humans: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages, blood neutroph...
- Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung.
- Pharmacokinetics and toxicity of inhaled human interferon-alpha in patients with lung cancer.
- Interferon gamma and thoracic irradiation in the treatment of unresectable stage IIIA/B non-small cell lung cancer.
- Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
- Immunological evidence for co-expression of cluster-5 and cluster-5A small cell lung cancer antigen on a single molecule.
- The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.
- Concurrent treatments and induction treatments for unresectable tumors.
- Normal lung biology.
- Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
- Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy.
- High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.
- Interferon trials in small cell lung cancer at one institution: a comparison of results obtained before and after initiation of systematic treatment trials using IFN-a...
- Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
- Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer.
- Inhaled recombinant interferon gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral b...
- The clinical effect of medroxyprogesterone (MPA) in elderly patients with lung cancer.
- Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy.
- Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity.
- High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.
- A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronch...
- Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer.
- Bronchoalveolar lavage fluid findings following radiotherapy for non-small cell lung cancer.
- Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
- Epirubicin in patients with inoperable non-small cell lung cancer--a phase II study.
- Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
- Concomitant and alternating radiation therapy (RT) and chemotherapy (CT) for inoperable, M0, non-small cell lung cancers (NSCLC): a consensus report.
- N-acetylcysteine in combination with radiotherapy in the treatment of non-small cell lung cancer: a feasibility study.
- Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feas...
- Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
- Inoperable non-small cell lung cancer: radiation with or without chemotherapy.
- Vincristine-cyclophosphamide, the classical two-drug regimen for small-cell lung cancer, evaluated in a randomized study with vindesine.
- Natural interferon-alpha alone and in combination with conventional therapies in non-small cell lung cancer. A pilot study.
- Computed tomography screening for lung cancer in asbestos-exposed workers.
- Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer.
- Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
- [A phase II multicenter study of gemcitabine in non small cell lung cancers].
- A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer.
- Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
- Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
- Quality of life assessment during chemotherapy for non-small cell lung cancer.
- Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study.
- Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
- Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
- Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
- Phase II study of weekly gemcitabine in advanced non-small cell lung cancer.
- Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
- A phase II trial of docetaxel in advanced non-small cell lung cancer.
- Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
- Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
- Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
- Tumour response and radiation-induced lung injury in patients with recurrent small cell lung cancer treated with radiotherapy and concomitant interferon-alpha.
- Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy.
- ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
- A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive ...
- Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC.
- Adjuvant and neoadjuvant treatments for NSCLC.
- Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study.
- Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
- A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
- Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.
- Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.
- Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.
- Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung can...
- Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
- Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
- Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
- Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
- Effect of chemotherapy for advanced non-small cell lung cancer on patients'' quality of life. A randomized controlled trial.
- Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 3...
Schools
University Of Minnesota Medical School
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1093791196 |
| Last Name Of The Provider | MATTSON |
| First Name Of The Provider | KARI |
| View All |
Similar Doctors
|
|
Dr. Melody A. Mendiola, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura L. Christenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Peterson, MD |
|
|
Dr. Thomas W. Martens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul F. Holten, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haritha N. Reddy, MD |
|
|
Dr. Robert S. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. M A. Rahman, MD |